by: Dr. Itay Gal
Thursday, 23 September 2021 | Israel’s health maintenance organizations (HMOs) will begin on Thursday providing the potentially life-saving COVID-19 treatment Regeneron to some patients at high risk of developing severe symptoms.
Among the recipients of the treatment are those suffering from obesity, heart and lung patients and unvaccinated individuals who are treated at home under the supervision of their health care provider.
Regeneron, an FDA-approved treatment with a proven track record in the United States to lower the number of hospitalizations, is a cocktail of two monoclonal antibodies designed to prevent at-risk COVID-19 patients in mild condition from developing severe illness that may end in hospitalization and even death.
Israel’s largest health care provider Clalit said that given the short Regeneron supplies, patients at higher risk may be prioritized over others as it pertains to the distribution of the treatment.
[Health Ministry Director-General Prof. Nachman Ash] noted that supplying HMOs with the treatment faced several logistical hurdles and that he and health officials were examining several options, hoping to resolve the issue soon.
To that end, Ash held a meeting with HMO chiefs and discussed making the treatment, which currently can only be prescribed by a private physician, accessible through public medicine as well.
Posted on September 23, 2021
Photo Credit: DMCA/pxfuel.com
All logos and trademarks in this site are property of their respective owner. All other materials are property of Bridges for Peace. Copyright © 2021.
Website Site Design by J-Town Internet Services Ltd. - Based in Jerusalem and Serving the World.